| Literature DB >> 18783612 |
Frank A Simmen1, Ying Su, Rijin Xiao, Zhaoyang Zeng, Rosalia C M Simmen.
Abstract
BACKGROUND: Krüppel-like factor 9 (KLF9) is a transcriptional regulator of uterine endometrial cell proliferation, adhesion and differentiation; processes essential for pregnancy success and which are subverted during tumorigenesis. The network of endometrial genes controlled by KLF9 is largely unknown. Over-expression of KLF9 in the human endometrial cancer cell line HEC-1-A alters cell morphology, proliferative indices, and differentiation, when compared to KLF9 under-expressing HEC-1-A cells. This cell line provides a unique model for identifying KLF9 downstream gene targets and signaling pathways.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18783612 PMCID: PMC2542371 DOI: 10.1186/1477-7827-6-41
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Primers used in quantitative real-time RT-PCR
| Gene Name | Upstream Primer (5'-3') | Downstream Primer (5'-3') | PCR product size (bp) |
| 18S | TCTTAGCTGAGTGTCCCGCG | ATCATGGCCTCAGTTCCG A | 150 |
| AKR7A2 | AACTGGACACGGCCTTCATG | CCTTGGTGGCAATTTTCACTCTG | 109 |
| ALDH1A1 | ACCCCAGGAGTCACTCAAGG | ACTGTGGGCTGGACAAAGTAG | 149 |
| BCAR3 | CCTGGAAATGCCACAGATCAC | CTTCATGCAGGAGTTTGCTGAA | 124 |
| C1orf186 | TAGCTTGGATAGCTCCTGCAGTTC | CATTTTTTAGTTCTCCAGGGTCAGA | 101 |
| CLIC4 | TCACCAAAACACCCAGAATCAA | ACCCCTCTCCAGTGCTTCATTA | 108 |
| COL4A1 | CACGGGTACTCTTTGCTCTACGT | AAGGGCATTGTGCTGAACTTG | 101 |
| COL4A2 | CATGCCCTTCCTGTACTGCAA | GATGTACTTGATCTCGTCCT | 133 |
| CXCR4 | CATCAGTCTGGACCGCTACC | GCAAAGATGAAGTCGGGAATAGTC | 138 |
| ER-α | CGGCATTCTACAGGCCAAATT | AGCGAGTCTCCTTGGCAGATT | |
| FZD5 | GCTACCAGCCGTCCTTCAGT | GAAGCGTTCCATGTCGATGAG | 128 |
| KLF4 | CTGCGGCAAAACCTACACAAA | GAATTTCCATCCACAGCCGT | 106 |
| KLF9 | TGGCTGTGGGAAAGTCTATGG | CTCGTCTGAGCGGGAGAACT | |
| LAMC2 | GATGGCATTCACTGCGAGAAG | TCGAGCACTAAGAGAACCTTTGG | 105 |
| LAPTM5 | CATCTTTTCCATCGCCTTCATCAC | TCCACCGAGTTCATGCACTTG | 102 |
| MAPKAPK3 | TCCCACCCTTCTACTCCAACA | TTCAACAGGAGGCGGATCA | 141 |
| NR3C1 | AGAGGAGGAGCTACTGTGAAGG | ACTGAGCCTTTTGGAAAATCAACC | 109 |
| PAX2 | CCCAGAGTGGTGTGGACAGTTT | GTAGGAAGGACGCTCAAAGACC | 101 |
| PSAT1 | ACGCCTCCATGTTTCAGCAT | TGAGATTTGATGGAGCTAAGCTTCT | 104 |
| PTCH1 | GTCGAGCTGTTCGGCATGAT | AGCAACGTGAACGGTGAACTC | 111 |
| RAB25 | GGAGCTCTATGACCATGCTGAA | CCAGGAAGAGCAGTCCATTGTT | 125 |
| RXRA | AGGACTGCCTGATTGACAAGC | GACTCCACCTCATTCTCGTTCC | 141 |
| SLPI | GCTGTGGAAGGCTCTGGAAA | TGCCCATGCAACACTTCAAG | 298 |
Figure 1Differentially expressed transcripts of HEC-1-A sub-lines. Venn diagrams summarize the number of differentially expressed genes noted between 2AS and 4S sub-lines, between 3AS and 9S sub-lines, and those in common for both comparisons (final annotated gene lists are presented in additional file 1: Table 1 and additional file 2: Table 2). There were greater numbers of genes induced than repressed in concert with relative KLF9 expression.
Figure 2Hierarchical clustering of differentially expressed RNAs. The microarray data for mRNAs that were identified to be differentially expressed between S and AS sub-lines (additional file 1: Table 1 and additional file 2: Table 2) were subjected to hierarchical clustering. The transcript profiles were very similar for both S sub-lines (each run in duplicate); whereas the two AS sub-lines differed from each other and from the S sub-lines. Lower case letters signify duplicate microarrays for each sub-line.
qRT-PCR confirmation of differential expression of selected transcriptsa
| BCAR3 | 3.907 | 2.488 | 1.171 | 2.611 |
| CLIC4 | 31.636 | 21.46 | 24.750 | 11.710 |
| COL4A1 | 3.387 | 3.584 | 1.768 | 2.179 |
| COL4A2 | 2.967 | 7.692 | 1.834 | 2.725 |
| CXCR4 | 5.000 | 2.762 | 13.037 | 3.876 |
| KLF4 | 4.532 | 2.110 | 1.816 | 3.185 |
| LAMC2 | 1.633 | 3.003 | 2.276 | 3.676 |
| LAPTM5 | 22.135 | 24.331 | 37.060 | 5.917 |
| MAPKAPK3 | 3.665 | 3.861 | 7.056 | 3.831 |
| NR3C1 | 7.111 | 2.841 | 12.500 | 4.386 |
| PSAT1 | 1.394 | 2.278 | 2.876 | 6.897 |
| PTCH1 | 3.572 | 4.310 | 3.008 | 2.242 |
| RXRα | 10.953 | 5.405 | 5.750 | 2.445 |
| SLPI | 26.636 | 9.524 | 4.788 | 11.779 |
| ALDHIAI | 0.222 | 0.174 | 0.109 | 0.068 |
| AKR7A2 | 0.647 | 0.491 | 0.264 | 0.387 |
| C1orf186 | 0.366 | 0.155 | 0.278 | 0.265 |
| FZD5 | 0.365 | 0.440 | 0.552 | 0.380 |
| PAX2 | 0.145 | 0.247 | 0.041 | 0.382 |
| RAB25 | 0.012 | 0.076 | 0.002 | 0.082 |
aAll fold change values were statistically significant (P < 0.05); n = 2 replicates per cell line.
Figure 3Quantitative RT-PCR of KLF9 mRNA in human endometrium and endometrial tumors. A normalized cDNA panel of human endometrial tumors was obtained from OriGene Technologies, Inc. This panel was comprised of cDNAs from n = 6 of normal (N) endometria, n = 9 of Stage I tumors, n = 8 of Stage II tumors, n = 19 of Stage III tumors, and n = 6 of Stage IV tumors. Shown are box plots (median, upper and lower quartiles, minimum and maximum data values) of relative abundance of KLF9 mRNA for tumors (delineated by stage and tumor type: endometrioid, serous). Sample numbers are indicated. ANOVA indicated no differences in mRNA abundance between any of the individual stages. However, a significant difference between combined stages (normal plus stage I vs. stages II, III, and IV) was noted by the Mann-Whitney Rank Sum test.